Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | ITGAL | P20701 | 7/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | ITGB2 | P05107 | 6/20 | 0.42 |
| ▸ | ICAM1 | P05362 | 6/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6196758 | 0.91 | MAPT (0.50) | MAPTSMN1; SMN2LMNAALDH1A1L3MBTL1 | |
| SCHEMBL5830431 | 0.91 | ALDH1A1 (0.57) | MAPTSMN1; SMN2LMNAALDH1A1L3MBTL1 | |
| SCHEMBL6197584 | 0.90 | MAPT (0.49) | MAPTSMN1; SMN2LMNAALDH1A1L3MBTL1 | |
| SCHEMBL6198632 | 0.90 | MAPT (0.63) | MAPTSMN1; SMN2LMNAALDH1A1L3MBTL1 | |
| SCHEMBL6198794 | 0.88 | MAPT (0.47) | MAPTSMN1; SMN2LMNAALDH1A1L3MBTL1 | |
| SCHEMBL6194851 | 0.87 | ITGAL (0.47) | MAPTSMN1; SMN2LMNAALDH1A1L3MBTL1 | |
| SCHEMBL6193706 | 0.87 | ITGB2 (0.51) | MAPTSMN1; SMN2LMNAALDH1A1L3MBTL1 | |
| SCHEMBL6198710 | 0.86 | MAPT (0.49) | MAPTSMN1; SMN2LMNAALDH1A1L3MBTL1 | |
| SCHEMBL6200004 | 0.85 | ITGB2 (0.50) | MAPTLMNAALDH1A1L3MBTL1PDE7A | |
| SCHEMBL6197780 | 0.83 | PDE7A (0.51) | MAPTSMN1; SMN2LMNAALDH1A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE39197-E1 | Cell adhesion-inhibiting antiinflammatory and immune-suppressive compounds | ABBOTT LABORATORIES (US) | 2006-07-18 | — | — | US | claimed |
| US-20050250768-A1 | Cell adhesion-inhibiting antiinflammatory and immune-suppressive compounds | ABBOTT LABORATORIES | 2005-11-10 | — | — | US | claimed |
| EP-1140814-B1 | CELL ADHESION-INHIBITING ANTIINFLAMMATORY AND IMMUNE-SUPPRESSIVE COMPOUNDS | ABBOTT LAB (US) | 2005-05-25 | — | — | EP | claimed |
| US-6878700-B1 | Cell adhesion-inhibiting antiinflammatory and immune-suppressive compounds | ABBOTT LABORATORIES (US) | 2005-04-12 | — | — | US | claimed |
| CN-1192018-C | Anti-inflammatory and immunosuppressive cell adhesion inhibiting compounds | ABBOTT LAB (US) | 2005-03-09 | — | — | CN | claimed |
| US-20040116518-A1 | Cell adhesion-inhibiting antiinflammatory and immune-suppressive compounds | ABBOTT LABORATORIES | 2004-06-17 | — | — | US | claimed |
| CN-1353691-A | Anti-inflammatory and immunosuppressive cell adhesion inhibiting compounds | ABBOTT LAB (US) | 2002-06-12 | — | — | CN | claimed |
| CN-1350520-A | Anti-inflammatory and immunosuppressive cell adhesion inhibiting compounds | ABBOTT LAB (US) | 2002-05-22 | — | — | CN | claimed |
| CN-1955164-A | Cell adhesion-inhibiting antiinflammatory and immune-suppressive compounds | ABBOTT LAB (US) | 2007-05-02 | — | — | CN | disclosed |
| US-RE39197-E1 | Cell adhesion-inhibiting antiinflammatory and immune-suppressive compounds | ABBOTT LABORATORIES (US) | 2006-07-18 | — | — | US | disclosed |
| US-20050250768-A1 | Cell adhesion-inhibiting antiinflammatory and immune-suppressive compounds | ABBOTT LABORATORIES | 2005-11-10 | — | — | US | disclosed |
| CN-1680338-A | Anti-inflammatory and immunosuppressive cell adhesion inhibiting compounds | ABBOTT LAB (US) | 2005-10-12 | — | — | CN | disclosed |
| EP-1140814-B1 | CELL ADHESION-INHIBITING ANTIINFLAMMATORY AND IMMUNE-SUPPRESSIVE COMPOUNDS | ABBOTT LAB (US) | 2005-05-25 | — | — | EP | disclosed |
| US-6878700-B1 | Cell adhesion-inhibiting antiinflammatory and immune-suppressive compounds | ABBOTT LABORATORIES (US) | 2005-04-12 | — | — | US | disclosed |
| CN-1192018-C | Anti-inflammatory and immunosuppressive cell adhesion inhibiting compounds | ABBOTT LAB (US) | 2005-03-09 | — | — | CN | disclosed |
| EP-1481968-A2 | Cell adhesion-inhibiting anti-inflammatory and immune-suppressive compounds | Abbott Laboratories (US) | 2004-12-01 | — | — | EP | disclosed |
| US-20040116518-A1 | Cell adhesion-inhibiting antiinflammatory and immune-suppressive compounds | ABBOTT LABORATORIES | 2004-06-17 | — | — | US | disclosed |
| CN-1353691-A | Anti-inflammatory and immunosuppressive cell adhesion inhibiting compounds | ABBOTT LAB (US) | 2002-06-12 | — | — | CN | disclosed |
| CN-1350520-A | Anti-inflammatory and immunosuppressive cell adhesion inhibiting compounds | ABBOTT LAB (US) | 2002-05-22 | — | — | CN | disclosed |
| US-6110922-A | ARYL SULFIDE CONTAINING PENDANT CIS- OR TRANS-CINNAMIDE GROUPS | ABBOTT LABORATORIES (US) | 2000-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050250768-A1 | Cell adhesion-inhibiting antiinflammatory and immune-suppressive compounds | ICAM1, VCAM1, EPCAM | MAPT 3667/4885SMN1; SMN2 3657/4885LMNA 2599/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.